Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Core Insights - Cybin Inc. has completed enrollment in its Phase 2 study for CYB004, a proprietary deuterated dimethyltryptamine (DMT) program aimed at treating Generalized Anxiety Disorder (GAD) [1] - The company reaffirms its top line data guidance for the study [1] Company Overview - Cybin Inc. is a clinical-stage neuropsychiatry company focused on advancing mental healthcare through innovative treatment options [1] - The company is listed on NYSE American and Cboe CA under the ticker symbol CYBN [1]